These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2307741)

  • 1. Fluoxetine in chronic schizophrenia.
    Lindenmayer JP; Vakharia M; Kanofsky D
    J Clin Psychopharmacol; 1990 Feb; 10(1):76. PubMed ID: 2307741
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy and safety of loxapine succinate in the treatment of schizophrenia: a comparative study with thiothixene.
    Vianna Filho U; Versiani Caldeira V; Romildo Bueno J
    Curr Ther Res Clin Exp; 1975 Sep; 18(3):476-90. PubMed ID: 810308
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of loxapine succinate in acute schizophrenia: a comparative study with thiothixene.
    van der Velde CD; Kiltie H
    Curr Ther Res Clin Exp; 1975 Jan; 17(1):1-12. PubMed ID: 806422
    [No Abstract]   [Full Text] [Related]  

  • 4. Fine motor performance before and after treatment in schizophrenic and schizoaffective patients.
    Goode DJ; Manning AA; Middleton JF; Williams B
    Psychiatry Res; 1981 Dec; 5(3):247-55. PubMed ID: 6948308
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyproheptadine in treatment-resistant chronic schizophrenics with prior negative response to fluoxetine.
    Bacher NM; Sanzone MM; Kaup B
    J Clin Psychopharmacol; 1994 Dec; 14(6):424-5. PubMed ID: 7884024
    [No Abstract]   [Full Text] [Related]  

  • 6. [Loxapine succinate: a new neuroleptic].
    Cottereau MJ; Poirier MF; Lôo H; Deniker P
    Encephale; 1979; 5(3):251-67. PubMed ID: 39739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine and schizophrenia in a patient with obsessional thinking.
    Baker RW
    J Neuropsychiatry Clin Neurosci; 1992; 4(2):232-3. PubMed ID: 1627986
    [No Abstract]   [Full Text] [Related]  

  • 8. Addition of fluoxetine to treatment of schizophrenic patients.
    Bacher NM; Ruskin P
    Am J Psychiatry; 1991 Feb; 148(2):274. PubMed ID: 1670983
    [No Abstract]   [Full Text] [Related]  

  • 9. Contribution of anticholinergic medication to symptom change in schizophrenia.
    DeQuardo JR; Kloss RJ
    J Clin Psychiatry; 1993 Sep; 54(9):356-7. PubMed ID: 8407855
    [No Abstract]   [Full Text] [Related]  

  • 10. Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient.
    D'Souza DC; Bennett A; Abi-Dargham A; Krystal JH
    J Clin Psychopharmacol; 1994 Oct; 14(5):361-3. PubMed ID: 7806697
    [No Abstract]   [Full Text] [Related]  

  • 11. Addition of fluoxetine to clozapine.
    Cassady SL; Thaker GK
    Am J Psychiatry; 1992 Sep; 149(9):1274. PubMed ID: 1503143
    [No Abstract]   [Full Text] [Related]  

  • 12. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice].
    Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC
    Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-resistant schizophrenia: controlled study of moderate- and high-dose thiothixene.
    Huang CC; Gerhardstein RP; Kim DY; Hollister L
    Int Clin Psychopharmacol; 1987 Jan; 2(1):69-75. PubMed ID: 3312398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of schizophrenia with obsessive-compulsive features with serotonin reuptake inhibitors.
    Hwang MY; Martin AM; Lindenmayer JP; Stein D; Hollander E
    Am J Psychiatry; 1993 Jul; 150(7):1127. PubMed ID: 8100402
    [No Abstract]   [Full Text] [Related]  

  • 15. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients.
    Goff DC; Brotman AW; Waites M; McCormick S
    Am J Psychiatry; 1990 Apr; 147(4):492-4. PubMed ID: 1969245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrodermal activity and therapeutic response to neuroleptic treatment in chronic schizophrenic in-patients.
    Schneider SJ
    Psychol Med; 1982 Aug; 12(3):607-13. PubMed ID: 7134318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia.
    Bartlett EJ; Wolkin A; Brodie JD; Laska EM; Wolf AP; Sanfilipo M
    Psychiatry Res; 1991 Oct; 40(2):115-24. PubMed ID: 1763142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive fluoxetine improves global function in chronic schizophrenia.
    Goldman MB; Janecek HM
    J Neuropsychiatry Clin Neurosci; 1990; 2(4):429-31. PubMed ID: 1983785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent.
    Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1978 Mar; 15(3):198-217. PubMed ID: 25167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double blind comparison of thiothixene and a trifluoperazine/chlorpromazine composite in the treatment of chronic schizophrenia.
    Knight RG; Harrison A
    N Z Med J; 1979 Apr; 89(634):302-4. PubMed ID: 377155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.